Coronary Artery Disease (CAD) Archives

FDA Approves Expanded PAD Indication for Xarelto Plus Aspirin

Approvals, Aspirin, Blockbusters, Coronary Artery Disease (CAD), Expanded Indication, FDA, Janssen, Johnson & Johnson, Peripheral Artery Disease (PAD), Therapeutics

The U.S. Food and Drug Administration approved an expanded peripheral artery disease indication for Janssen’s Xarelto (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization due to symptomatic PAD.

August 24, 2021/by Andrew Humphreys

AstraZeneca’s heart drug gets FDA nod

Approvals, Aspirin, Blockbusters, Clinical Trials, Coronary Artery Disease (CAD), FDA, FDA/Regulatory, Heart Attacks, Stroke

The U.S. Food and Drug Administration approved AstraZeneca Plc’ drug for reducing the risk of a first heart attack or stroke in high-risk patients with coronary artery disease.

June 1, 2020/by Reuters Health

FDA approves Bayer’s Gadavist injection

Approvals, Blood Vessels, Contrast Agents, Coronary Artery Disease (CAD), Diagnostic Tools, FDA, FDA/Regulatory, Heart Attacks, rest)

The FDA approved Gadavist for use in cardiac magnetic resonance imaging to assess myocardial perfusion and late gadolinium enhancement in adults with known or suspected CAD.

July 15, 2019/by PR Newswire

Azurity Pharmaceuticals Wins FDA Approval for Liquid Form of Amlodipine

Adults, Approvals, Coronary Artery Disease (CAD), FDA, FDA/Regulatory, Hypertension, Pediatric

Privately held Azurity Pharmaceuticals won approval for a liquid form of a hypertension drug for both adult and pediatric patients.

July 10, 2019/by BioSpace